The specialty pharma that does not invent the drug. It finds the patients the drug was always meant to reach.
Somewhere in Deerfield, Illinois, about 220 people manage a small shelf of drugs you have probably never heard of unless you, or someone you love, needed one of them very badly. There is no blockbuster here. There is no molecule with TerSera's name stamped on its patent. What there is, instead, is a deliberate, almost stubborn idea: that a good medicine should not go quiet just because the company that made it lost interest.
That is the whole company in one sentence. TerSera Therapeutics acquires specialty medicines - approved or nearly approved - in oncology, rare disease, and non-opioid pain, and then does the unglamorous work of keeping them available, supported, and prescribed correctly. It is pharmaceuticals with the discovery risk subtracted and the commercial discipline turned up.
Here is an awkward truth about the drug business. A medicine can work, be approved, and still become an orphan inside a giant company - too small to matter on a megacap balance sheet, too important to the patients on it to simply let drift. Sales forces get reassigned. Marketing budgets evaporate. The drug keeps working; the company keeps moving.
Consider the patients at the sharp end of that math. People with carcinoid syndrome, where metastatic neuroendocrine tumors make ordinary days unlivable. People in severe chronic pain who cannot tolerate opioids. People with hormone-driven cancers. These are not large markets. They are exactly the markets a company optimizing for its next blockbuster is tempted to overlook.
The tension TerSera lives inside is simple to state and hard to run: how do you make a sustainable business out of medicines too small for the giants but too necessary to abandon? Answer that, and you have a company. Fumble it, and you have a warehouse of expiring inventory.
In February 2016, the Chicago private equity firm GTCR partnered with industry veteran Edward J. Fiorentino - a former president of Abbott Diabetes Care - to build a company around that exact gap. The vehicle, once known as JDP Therapeutics, was relaunched as TerSera. The thesis was contrarian for its calm: skip the lottery ticket of early drug discovery, and instead acquire medicines that already cleared the regulatory gauntlet, then commercialize them with focus.
It is, admittedly, a less romantic story than a lab breakthrough. Nobody writes a movie about a thoughtfully executed asset acquisition. But the bet has a logic that compounds: every approved product TerSera takes on arrives with proof it works. The risk that remains is execution - and execution is a thing you can actually control.
"TerSera is building the new cornerstones of care and ensuring they are delivered to the people who need them."
Company mission statement, tersera.comThe first move proved the model. TerSera bought U.S. and Canadian rights to ZOLADEX from AstraZeneca - a company plenty large enough to have other priorities. For TerSera, that single product was a cornerstone. For AstraZeneca, it was housekeeping. The mismatch is the entire opportunity.
Five medicines, three therapy areas, one organizing principle: each one was overlooked, underserved, or both - until someone decided it was worth the trouble.
Telotristat ethyl. The first and only FDA-approved oral therapy for carcinoid syndrome diarrhea, used alongside somatostatin analog therapy. A pill for a problem that used to have none.
Ziconotide. The only FDA-approved non-opioid intrathecal infusion treatment for severe chronic pain - for patients out of other options. Divested to ESTEVE in 2026.
Goserelin. A hormone-based oncology therapy and TerSera's very first acquisition, bought from AstraZeneca in 2016. The cornerstone the whole company was built on.
Rolapitant. An antiemetic that helps prevent chemotherapy-induced nausea and vomiting - the kind of supportive care that makes treatment survivable.
Cetirizine injection. Part of the Infusion Specialty Therapies unit divested to ESTEVE in 2026, as TerSera narrowed its aim.
GTCR partners with Ed Fiorentino to launch TerSera from the former JDP Therapeutics, headquartered in Deerfield, IL.
First acquisition. TerSera buys U.S. and Canadian rights to ZOLADEX from AstraZeneca - the company's founding cornerstone.
XERMELO enters the market as the first and only approved oral therapy for carcinoid syndrome diarrhea (FDA approval Feb 2017).
Portfolio expansion. GTCR and TerSera announce the acquisition of XERMELO, deepening the rare-disease franchise.
Updated PACC guidelines issue new guidance relevant to administering PRIALT, reinforcing its clinical place in pain care.
Real-world data on intrathecal ziconotide (PRIALT) prescription patterns presented at ASPN 2025.
Strategic sharpening. ESTEVE agrees to acquire TerSera's Infusion Specialty Therapies unit (PRIALT, Quzyttir), letting TerSera refocus on oncology and rare disease.
The case for TerSera is not in its size - it is in its concentration. A lean organization, a handful of specialized products, and a 2026 divestiture that deliberately made the company smaller in order to make it sharper. That last move is the tell: companies chasing scale do not sell off a working business unit. Companies chasing focus do.
Backing has come from GTCR and, in growth and debt capital, Oaktree Capital Management. Partnerships have run in both directions - buying ZOLADEX from AstraZeneca on the way in, selling the infusion unit to ESTEVE on the way to sharper focus. The capital is patient because the model demands patience. Specialty pharma is not a sprint; it is a long, careful relay.
Strip away the corporate language and TerSera's mission is unusually concrete. Find medicines with untapped potential. Keep them available. Support the patients and physicians who depend on them. The word the company keeps returning to is "cornerstone" - not breakthrough, not disruption. A cornerstone is something you build the rest of the structure on, and then mostly forget is there. That is a strangely honest metaphor for what TerSera does.
Leadership has evolved with the mission. Founder Ed Fiorentino moved to executive chairman; Edward Donovan stepped in as CEO. The medical and research function is led by chief medical officer Ahsan Arozullah, MD, MPH. The roster is small for a company running multiple FDA-approved products - which is, again, the point.
"We follow the science toward therapies with untapped potential."
TerSera TherapeuticsThe drug industry will keep producing orphans. Every merger, every pipeline reprioritization, every quarterly reshuffle leaves working medicines without a champion. As long as that is true, there is room for a company whose entire job is to be the champion - to take the medicine too small for a giant and treat it as a cornerstone instead of a footnote.
That is the bet TerSera is still making, ten years in, now more concentrated than ever. Whether the model scales is an open question. Whether it matters to the patient holding the prescription is not.
So return to that quiet office on Lake Cook Road. The 220 people are still there, still managing a small shelf of drugs most people will never hear of. But somewhere, a patient with carcinoid syndrome takes a pill that did not exist as an option a decade ago. Someone in chronic pain gets a non-opioid alternative. The medicines did not go quiet. That is the whole point - and it turns out to be enough to build a company on.
Video links open YouTube search results - we point you to the source rather than guess at a single URL.